Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edralbrutinib - Eternity Bioscience/TG Therapeutics

Next Previous
Drug Profile

Edralbrutinib - Eternity Bioscience/TG Therapeutics

Alternative Names: EBI-1459; SHR-1459; TG-1701

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eternity Bioscience
  • Developer Eternity Bioscience; Jiangsu Hengrui Medicine Co.; Reistone Biopharma; TG Therapeutics
  • Class Amines; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenyl ethers; Pyridazines; Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Membranous glomerulonephritis; Neuromyelitis optica; Non-Hodgkin's lymphoma
  • Preclinical Multiple sclerosis
  • No development reported B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy) in China (PO, Tablet)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Monotherapy, Recurrent, Second-line therapy or greater) in China (PO, Tablet)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in Australia (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top